Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01643980
Other study ID # PESAPRO-2012
Secondary ID 2012-000241-13
Status Completed
Phase Phase 4
First received June 12, 2012
Last updated October 14, 2016
Start date August 2012
Est. completion date April 2016

Study information

Verified date October 2016
Source Puerta de Hierro University Hospital
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. The investigators propose a clinical trial with the objective to identify effective strategies to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.

The investigators intend to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries. These 2 strategies are affordable, easy to apply, and they present very few maternal-fetal secondary effects.


Description:

The preterm birth is considered as a main problem in the modern obstetrics, being the responsible of greatest of 50% neonatal morbimortality and heavy costs. Despite the significant medical advances, the rate of prematurity has not declined over the past 40 years and even continues to rise in the developed countries. In order to decrease the prematurity is necessary that two premises: to identify the pregnant women at risk of preterm birth, and dispose of useful measures aimed at prolonging the pregnancy and therefore avoid preterm delivery. Since 1990, many published articles describe the sonographic measurement of the cervix from the week 16 as method of population screening to detect women at risk. Several studies provide evidence about an inverse relationship between the cervical length and the risk of preterm delivery. For this reason, if there is an effective intervention for patients with cervix short (about < 25mm), made this measure in the middle of the second term, the investigators could reduce the prematurity. Regarding possible therapeutic strategies, recent published data demonstrate the effective of vaginal progesterone and cervical pessary in this population. However, both treatments have never been compared and none of the two strategies are indicated in this population. Therefore it results necessary to compare both treatments in order to establish clinical recommendations. The investigators propose a clinical trial to compare two accepted strategies: administration of progesterone (vaginally) or the placement of vaginal pessaries in order to reduce the premature birth (34 weeks and earlier) rate in the population of pregnant women at risk for premature birth, which will be identified by ultrasound during the second trimester of their pregnancy.


Recruitment information / eligibility

Status Completed
Enrollment 254
Est. completion date April 2016
Est. primary completion date March 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pregnant women with short cervix (=< 25 mm) identified by use of routine transvaginal ultrasonography at 19-22 weeks of gestation.

- Single pregnancy

- Women older than 18 year-old

- Women sign informed consent according GCP and local legislation

- Gestational age at randomization between 20+1 and 23+6 weeks.

Exclusion Criteria:

- Major fetal abnormalities

- Major uterine abnormalities

- Placenta praevia during current pregnancy

- Vaginal bleeding or ruptured membranes in the moment of randomization

- Cervical cerclage in situ

- History of cone biopsy

- Allergic to peanuts

- Contraindication for Progesterone usage.

- Active treatment with Progesterone at randomization.

- History of 3 or more premature labor.

- If in the investigator's opinion, there are findings on physical examination, abnormalities in the results of clinical analyzes or other medical factors, social or psycho-social that could negatively influence.

- Women unable to give the informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Vaginal micronized progesterone
200 mg vaginal route per day
Device:
Cervical pessary
Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)

Locations

Country Name City State
Spain University Hospital Príncipe de Asturias Alcalá de Henarés Madrid
Spain University Hospital Fundación de Alcorcón Alcorcón Madrid
Spain University Hospital Quiron Dexeus Barcelona
Spain University Hospital Madrid Monte Principe Boadilla del Monte Madrid
Spain Burgos University Hospital Burgos
Spain Ciudad Real General University Hospital Ciudad Real
Spain Hospital Universitario de Donostia Donostia San Sebastian
Spain University Hospital Fuenlabrada Fuenlabrada Madrid
Spain Palamos Hospital Gerona Palamos
Spain University Hospital de Getafe Getafe Madrid
Spain Guadalajara General University Hospital Guadalajara
Spain Igualada Hospital Igualada Barcelona
Spain University Hospital Severo Ochoa Leganés Madrid
Spain University Hospital de León León
Spain Sanitas La Moraleja Hospital Madrid
Spain Sanitas La Zarzuela Hospital Madrid
Spain University Hospital Ramón y Cajal Madrid
Spain University Hospital Puerta de Hierro Majadahonda Madrid
Spain University Hospital Quirón Málaga Málaga
Spain University Hospital Rey Juan Carlos I Mostoles Madrid
Spain University Hospital Mostoles Móstoles Madrid
Spain Hospital Infanta Sofía San Sebastián de los Reyes Madrid
Spain University Hospital San Juan de Alicante Sant Joan d'Alacant Alicante
Spain Hospital Infanta Elena Valdemoro Madrid
Spain University Hospital Rio Hortega Valladolid
Spain Valladolid Clinic Universitary Hospital Valladolid
Spain University Hospital Miguel Servet Zaragoza

Sponsors (1)

Lead Sponsor Collaborator
Dra.Cristina Martinez Payo

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of spontaneous preterm birth before 34 weeks of gestation up to 11 weeks (from date of randomization until delivery) No
Secondary Proportion of spontaneous preterm birth before 37 weeks of gestation up to 17 weeks (from date of randomization until delivery) No
Secondary Proportion of Spontaneous preterm birth before 28 weeks of gestation up to 8 weeks (from date of randomization until delivery) No
Secondary Rate of premature rupture of membranes before 34 weeks of gestation up to 11 weeks (from date of randomization until delivery) No
Secondary Weight at birth up to 21 weeks (from date of randomization until delivery) No
Secondary Rate of fetal and neonatal mortality From date of randomization until the date of delivery, assessed up 21 weeks No
Secondary Symptomatic vaginal infections during treatment period From date of randomization until the date of delivery, assessed up 21 weeks No
Secondary Proportion of participants with adverse events From date of randomization until the date of delivery, assessed up 21 weeks Yes
Secondary Rate of Chorioamnionitis during third term From date of randomization until the date of delivery, assessed up 21 weeks No
Secondary Need of admission because of premature labor before 34 weeks of gestation up to 14 weeks (from date of randomization until delivery) No
Secondary Rate of neonatal morbidity From date of randomization until the date of delivery, assessed up 21 weeks No